Background: Lowering the dose of desoxycorticosterone pivalate (DOCP) for the
Medicines Agency and in 2016 by the FDA. 2, 3 Zycortal is produced by a different manufacturer than Percorten-V and differs slightly from the latter with regard to the preservative (chlorocresol rather than thimerosal) and the surfactant (polysorbate-60 rather than polysorbate-80).
It is the only product licensed in Europe for the treatment of PH. In July 2018, because of a shortage of Percorten-V, the FDA proposed Zycortal as an alternative. In pharmacological studies, the effectiveness of Zycortal was shown to be "noninferior" to that of Percorten-V and the same starting dosage of 2.2 mg/kg every 25 days was recommended by the manufacturer.
Because the expense of DOCP can be a limiting factor for some owners, finding the lowest effective dose for each dog is important. In previous studies using the originally licensed DOCP (Percorten-V), it was shown that in the majority of dogs the clinical disease can be well controlled with substantially lower dosages than the recommended 2.2 mg/kg. [4] [5] [6] Another strategy to decrease treatment costs is prolongation of the injection interval. 6 The duration of action of DOCP (Percorten-V) has been shown to range from 32 to 94 days in dogs newly diagnosed with PH. 6 However, in no published study has a fixed starting dosage of DOCP been evaluated. Furthermore, to our knowledge, no studies have evaluated whether, using the newly registered DOCP product (Zycortal), lower doses than recommended by the manufacturer are effective in controlling clinical signs.
Thus, the aims of our study were to evaluate a low-dose treatment protocol using the new DOCP product (Zycortal) in dogs with naturally occurring PH and to identify the lowest possible dose needed to obtain a monthly injection interval of 28-30 days. In dogs previously treated with PO FC, the starting dosage of prednisolone was 0.1 mg/kg per day.
| MATERIALS AND METHODS

| Animals
| Treatments
| Study design
A minimum follow-up period of >3 months was necessary to be included in the study. The DOCP dosage and serum Na and K concentrations were recorded at the time of inclusion and after 1-2, 2-3, 3-6, 6-12, 12-18, 18-24, and >24 months during follow-up. All variables were recorded on the day of the DOCP injection.
All procedures were conducted in accordance with guidelines established by the Animal Welfare Act of Switzerland. In addition, informed consent of the pet owners was obtained before including dogs in the study. Figure 1 ).
| Statistical analysis
At the first reevaluation, the DOCP dose was decreased and the injection interval increased because of hypokalemia in 15 dogs. At the second reevaluation, the DOCP dose was decreased in 7 dogs, and in 5 of the 7 dogs, the injection interval was increased. Injection intervals for the first 3 months of treatment of all dogs are presented in Table 2 . In 2 dogs, the DOCP dose first had to be increased and later during the follow-up period decreased again. One of the 2 dogs was a 4-month-old Dachshund. In this dog, the DOCP dosage was increased 2.4 months after inclusion from 1.5 to 1.7 mg/kg. Nine months after inclusion (at the age of 13 months), however, the DOCP dosage had to be decreased to 1.5 mg/kg again and 2 months later to 1.0 mg/kg. The second dog was a 3-year-old Great St. Bernard, which, because of financial concerns, first had been treated with PO FC. The FC dose had to be continually increased because of serum electrolyte concentrations outside the reference interval. After 6 months, treatment was finally changed to DOCP because of glucocorticoid-associated adverse effects (polyuria, polydipsia, muscle loss) despite discontinuation of prednisolone. The dog was started on a DOCP dosage of 1.2 mg/kg, but the dosage had to be increased to 1.3 and 1.6 mg/kg after 1.7 and 2.7 months, respectively. After 4.3 months, the DOCP dosage was steadily decreased to a final dosage of 0.7 mg/kg, which was reached after 28.5 months of treatment.
In dogs with ≤3 years of age (7 dogs), the DOCP dose 3 months after starting treatment was significantly higher compared to dogs >3 years of age (10 dogs; P = .03).
No significant difference in Zycortal dosage was found between dogs previously treated with FC and those that were immediately started on Zycortal.
| Serum K concentrations
Serum K concentrations decreased during DOCP treatment. The decrease compared over all reevaluations, however, was not statistically significant (Friedman test, P = .81). Results (median, range) at different time points during reevaluation are presented in Table 1 and Figure 2 .
| Serum Na concentration
Serum Na concentrations increased during DOCP treatment. The increase compared over all reevaluations, however, was not statistically significant (Friedman test, P = .16). Results (median, range) at different time points during reevaluation are presented in Table 1 and 
| DISCUSSION
We were able to show that all dogs with PH, started on a lower DOCP dosage than recommended by the manufacturer, could be effectively treated and stabilized.
Pharmacological studies by the manufacturer had shown that DOCP (Zycortal) administered at the dosage of 2.2 mg/kg was well tolerated in purpose-breed beagle dogs. Even dose increases up to as much as 5-fold the labeled dosage for 6 months did not seem harmful. Determination of plasma renin activity (PRA) is the most sensitive marker in human medicine for identifying insufficient as well as excessive mineralocorticoid replacement. 10 In a previous study, we found completely suppressed (ie, below the detection limit of the assay) PRA concentrations in dogs with PH treated with the original DOCP product (Percorten-V). 11 In human medicine, this is a clear indication of excessive treatment with mineralocorticoids and can indicate a risk for iatrogenic hypertension and potential long-term complications in these patients. 10 Short-term treatment of dogs with 2.2 mg/kg DOCP (Percorten-V) did not lead to hypertension, 12 but long-term studies including determination of PRA as a monitoring tool and measurement of blood pressure during treatment have not yet been performed in dogs. 12 Therefore, in our study, despite serum Na and K concentrations within the reference interval, dogs still could have been exposed to inappropriately high doses of DOCP. Hence, veterinarians should strive to find the lowest possible dose of DOCP, not only to achieve lower treatment costs but also for safety reasons to avoid possible, as yet undescribed, adverse effects of long-term overtreatment.
Despite decreases in serum K concentrations below the reference interval, development of severe hypernatremia has not been described, neither in our study (only 1 dog with mildly increased serum Na concentration 3 months after starting treatment) nor in previous studies using the original DOCP product (Percorten-V). This is not surprising, because in healthy Beagle dogs receiving up to 5 times the labeled dosage of Zycortal, either normonatremia or only mild hypernatremia was observed. 2 Mineralocorticoid excess is known to lead to "aldosterone escape," characterized by increased renal perfusion and natriuresis, which prevents nonphysiologically high increases in serum Na concentration. 13, 14 A DOCP dose increase was necessary in only 2 dogs. One dog was a puppy in which the dosage had to be increased to 1.7 mg/kg.
Interestingly, at the ages of 13 and 15 months (at the time of manuscript preparation), the dosage could be decreased to 1.5 and 1 mg/kg, respectively. We assume that this change corresponded with the end of the dog's growth period. Also, in another study, the DOCP dose had to be increased in a 4-month old dog, which was attributed to the dog's continued growth. 5 However, it also could be a sign of young age independent of growth, meaning that at older ages, lower dosages are needed. In fact, we were able to show a significant difference in the DOCP dose when comparing younger to older dogs. This phenomenon also has been observed in another study using the original DOCP product (ie, a higher dosage was needed in younger than in older dogs). 6 Interestingly, registration and approval documents of the manufacturer show that their healthy research Beagle dogs were between 5 and 6 months of age. 1, 3 This seems a likely explanation for the manufacturer's recommendation of a relatively high 2.2 mg/kg starting dosage.
In a double-blinded 180-day field study by the manufacturer, Zycortal was found to be "noninferior" to Percorten-V, and a mean injection interval of 38.5 ± 12.5 days with a range of 20-99 days was observed. 2 Also in a study using Percorten-V in dogs newly diagnosed with PH, the investigators were able to show that serum K and Na concentrations could be maintained within the reference interval for a median duration of 62 days, with a range of 32-94 days, using a dosage of 2.2 mg/kg. 6 Based on these results, the injection interval using a high starting dosage, may be highly variable with both products and may be as long as 99 days. For owners, however, considerable and improved control of serum Na concentrations. This observation also was made in earlier studies using Percorten-V. 4, 11 Potential limitations of our study are the low number of dogs and the lack of PRA determination as a monitoring tool, as discussed above. Considering the case number, we can say that, although low, in none of the dogs was the high dosage of 2.2 mg/kg needed.
Moreover, a significantly lower dosage than our already low starting dosage of 1.5 mg/kg was needed, with decreases to dosages as low as 0.35 mg/kg. Therefore, the 2.2 mg/kg dosage recommended by the manufacturer seems too high to maintain dogs at a targeted injection interval of 28-30 days.
In conclusion, DOCP dosage is highly variable and should be titrated to the needs of each individual animal. A starting dosage of 1.5 mg/kg seems adequate in the majority of dogs. In all but 2 dogs, decreasing doses were necessary to obtain an injection interval of 28-30 days and to avoid overdosing as assessed by serum electrolyte concentrations outside the reference interval. Dosages higher than 1.5 mg/kg may be needed in young growing dogs. Further studies are needed to confirm this suspicion.
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